176 related articles for article (PubMed ID: 12883977)
1. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients.
Zhang D; Lapeyraque AL; Popon M; Loirat C; Jacqz-Aigrain E
Pediatr Nephrol; 2003 Sep; 18(9):943-8. PubMed ID: 12883977
[TBL] [Abstract][Full Text] [Related]
2. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
[TBL] [Abstract][Full Text] [Related]
5. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
7. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
Pescovitz MD; Brook B; Jindal RM; Leapman SB; Milgrom ML; Filo RS
Clin Transplant; 1997 Dec; 11(6):613-7. PubMed ID: 9408695
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics.
Filler G; Lampe D; von Bredow MA; Lappenberg-Pelzer M; Rocher S; Strehlau J; Ehrich JH
Pediatr Nephrol; 1998 Jan; 12(1):6-9. PubMed ID: 9502557
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients.
Wong DD; van Zuylen WJ; Craig ME; Rawlinson WD
Rev Med Virol; 2019 Mar; 29(2):e2023. PubMed ID: 30556615
[TBL] [Abstract][Full Text] [Related]
11. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection.
Tornatore KM; Garey KW; Saigal N; Reed K; Murray B; Ingalls E; DiFrancesco R; Forrest A; Morse G; Venuto R
Clin Transplant; 2001 Oct; 15(5):297-308. PubMed ID: 11678955
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.
Chamberlain CE; Penzak SR; Alfaro RM; Wesley R; Daniels CE; Hale D; Kirk AD; Mannon RB
Am J Transplant; 2008 Jun; 8(6):1297-302. PubMed ID: 18444933
[TBL] [Abstract][Full Text] [Related]
13. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
[TBL] [Abstract][Full Text] [Related]
14. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
15. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
16. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group.
Frenkel LM; Capparelli EV; Dankner WM; Xu J; Smith IL; Ballow A; Culnane M; Read JS; Thompson M; Mohan KM; Shaver A; Robinson CA; Stempien MJ; Burchett SK; Melvin AJ; Borkowsky W; Petru A; Kovacs A; Yogev R; Goldsmith J; McFarland EJ; Spector SA
J Infect Dis; 2000 Dec; 182(6):1616-24. PubMed ID: 11069232
[TBL] [Abstract][Full Text] [Related]
17. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
[TBL] [Abstract][Full Text] [Related]
18. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
20. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
Nawashiro Y; Shiraki K; Yamamoto S; Takizawa K; Sasada Y; Suehiro M; Miura K; Hattori M; Daikoku T; Hisano M
Transplant Proc; 2018 Dec; 50(10):3932-3936. PubMed ID: 30577289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]